TGFb1 Receptor Kinase Inhibitor Inhibits Prostate Cancer Growth in Bone
Bone metastases (BM) are the primary cause of morbidity and mortality of prostate cancer (PCa) and no effective therapy is currently available. Transforming growth factor (TGF)-β1 has been implicated in the pathophysi ology of PCa BM. TGF-t31 is a pleiotropic growth factor that regulates cellular proliferation, chemotaxis, cellular differentiation, immune response, and angiogenesis. TGF-β1 receptors are transmembrane serine/threonine kinases. Upon TGF-β1 binding the type II receptor associates with and phosphorylates the type I receptor to initiate signaling. In the present work we tested the antitumor efficacy of a selective TGFt31 receptor kinase inhibitor (LY2109761, Eli Lilly and Co) in preclinical models of PCa BM. For these studies we used two bone derived PCa cell lines, MDA PCa 2b and PC3 cells.
前列腺癌 骨转移瘤 转化生长因子受体 激酶抑制剂
Zhigang LI Qinghua ZHOU Nora NAVONE
国内会议
天津
英文
699
2009-07-03（万方平台首次上网日期，不代表论文的发表时间）